|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
<b>Abbreviations:</b> ESCs: endometrial stromal cells; 17β-E2: 17β-Estradiol; EMT: epithelial-mesenchymal transition; CASP3: caspase 3; BCL2: B cell leukemia/lymphoma 2; VEGFA: vascular endothelial growth factor A; lncRNA: long non-coding RNA; GAPDH: glyceraldehyde-3-phosphate dehydrogenase; RT-qPCR: reverse transcription-quantitative polymerase chain reaction.
|
30608887 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
<b>Background:</b> B-cell leukemia/lymphoma-2 (BCL-2) protein is an important part of apoptotic pathway, which is overexpressed in chronic lymphocytic leukemia cells, non-Hodgkin lymphoma cells, and myeloma cells.
|
31293422 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
<b>Purpose:</b> The oral BCL-2 inhibitor venetoclax is an effective therapy for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL), including disease with high-risk genomic features such as chromosome 17p deletion [del(17p)] or progressive disease following B-cell receptor pathway inhibitors.<b>Patients and Methods:</b> We conducted a comprehensive analysis of the safety of 400 mg daily venetoclax monotherapy in 350 patients with CLL using an integrated dataset from three phase I/II studies.<b>Results:</b> Median age was 66 years and 60% had del(17p).
|
29895707 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Chronic lymphocytic leukemia (CLL), the most frequent leukemia in adults in the Western world, is characterized by predominantly nondividing malignant CD5+ B cells overexpressing the anti-apoptotic Bcl2 protein.
|
16616063 |
2006 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
CLL therapies targeting Bcl-2 may need to be modified to antagonize proliferation centre-specific pro-survival proteins.
|
17760804 |
2007 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
B-cell leukemia/lymphoma 2 (BCL-2) prevents commitment to programmed cell death at the mitochondrion.
|
24346116 |
2014 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
CLL cells switch from highly sensitive for BCL-2 inhibition to resistant after CD40-stimulation.
|
27689871 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
B-cell leukemia/lymphoma 2 (Bcl-2) family proteins regulate apoptotic pathway that can be targeted with small molecule inhibitors.
|
28586007 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
B cell leukemia/lymphoma-2 (Bcl-2) suppresses apoptosis by binding the BH3 domain of proapoptotic factors and thereby regulating mitochondrial membrane potential (MMP).
|
28843007 |
2018 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
BCL2 translocations in CLL appear to arise via a different mechanism from comparable translocations seen in B cell non-Hodgkin lymphoma.
|
12040429 |
2002 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BCL2 protein levels in CLL reflect a complex interplay of transcriptional and posttranscriptional controls, but do not appear to be associated with the -938C>A promoter SNP.
|
17959858 |
2008 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Bcl-2 family proteins play a critical role in the regulation of apoptosis in chronic lymphocytic leukemia (CLL).
|
18599795 |
2008 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BCL2-938C>A polymorphism and disease progression in chronic lymphocytic leukemia.
|
19883311 |
2009 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
BCL-2, PLAG1 is a putative new relevant oncogene involved in the pathogenesis of CLL.
|
20687796 |
2010 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
BCL-2 (B-cell leukemia/lymphoma 2) gene has been demonstrated to be associated with breast cancer development and a single nucleotide polymorphism (SNP; -938C > A) has been identified recently.
|
21457555 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Bcl-2 is an important target in CLL.Antisense therapy is a novel approach to target oncoproteins; this can be beneficial in the clinical setting.
|
21521129 |
2011 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
BCL2 is a valid therapeutic target in CLL, and its inhibition by navitoclax warrants further evaluation as monotherapy and in combination in this disease.
|
22184378 |
2012 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
BCL-2 family proteins regulate apoptosis and over-expression of anti-apoptotic B-cell leukemia/lymphoma 2 (BCL-2) family proteins has been associated with chemotherapeutic resistance in APL including impairment of the ability of atRA to induce growth arrest and differentiation.
|
25088254 |
2014 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
BCL2 (B-cell leukemia/lymphoma 2) gene functions as antiapoptotic regulatory element and known to be associated with tumorigenesis.
|
26662799 |
2016 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Bcl-2 protein expression and p53 gene mutation in chronic lymphocytic leukemia: correlation with in vitro sensitivity to chlorambucil and purine analogs.
|
9107076 |
1997 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Gly101Val BCL2 Mutation: One Step Closer to Understanding Venetoclax Resistance in CLL.
|
30824485 |
2019 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
t(18;22)(q21;q11) with rearrangement of BCL2 as a possible secondary change in a lymphocytic lymphoma.
|
1868035 |
1991 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
A number of new treatment options have recently emerged for chronic lymphocytic leukemia (CLL) patients, including the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib, phosphatidylinositol-3-kinase (PI3K) delta isoform inhibitor idelalisib combined with rituximab, the Bcl-2 antagonist venetoclax, and the new anti-CD20 antibodies obinutuzumab and ofatumumab.
|
28185174 |
2017 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
A search for bcl1, bcl2, and c-myc oncogene rearrangements in chronic lymphocytic leukemia.
|
2642578 |
1989 |
|
Chronic Lymphocytic Leukemia
|
0.500 |
Biomarker
|
disease |
BEFREE |
Abbreviations: APC/C: Anaphase-Promoting Complex/Cyclosome; BAD: BCL2-Associated agonist of cell Death; BAK1: BCL2 Antagonist Kinase1; BAX: BCL2-Associated X; BCL2: B-cell Chronic Lymphocytic Leukaemia (CLL)/Lymphoma 2; BH: BCL2 Homology Domain; BID: BH3-Interacting domain Death agonist; BIM: BCL2-Interacting Mediator of cell death; BUB: Budding Uninhibited by Benzimidazoles; CDC: Cell Division Cycle; CDH1: Cadherin-1; CDK1: Cyclin-Dependent Kinase 1; CEP55: Centrosomal Protein (55 KDa): CIN: Chromosomal Instability; CTA: Cancer Testis Antigen; EGR1: Early Growth Response protein 1; ERK: Extracellular Signal-Regulated Kinase; ESCRT: Endosomal Sorting Complexes Required for Transport; GIN: Genomic Instability; MAD2: Mitotic Arrest Deficient 2; MCL1: Myeloid Cell Leukemia sequence 1; MPS1: Monopolar Spindle 1 Kinase; MYT1: MYelin Transcription factor 1; PLK1: Polo Like Kinase 1; PUMA: p53-Upregulated Mediator of Apoptosis; SAC: Spindle Assembly Checkpoint; TAA: Tumor-Associated Antigen.
|
30601084 |
2019 |